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medications, to assess its impact on healthcare costs, and to
deduce areas for further research. METHODS: A systematic lit-
erature search (1990–2004) using an exhaustive list of relevant
search terms was performed to identify articles with qualitative
and quantitative data on adherence with oral anti-diabetic agents
(OAs) and insulin. Studies describing the economic impact of
non-adherence, including impact of medication co-payment on
level of adherence, were also reviewed. Electronic Medline® and
PubMed® searches along with manual review of bibliographies
were conducted in different phases for article retrieval.
RESULTS: Adequate documentation of adherence and its eco-
nomic impact was found in 51 studies. Most adherence studies
were conducted on OAs. Thirty-seven retrospective studies
showed that adherence to diabetes treatment ranged from 31%
to 90%, mostly measured by medication possession ratio, with
levels slightly lower among insulin patients. Results varied due
to a diversity of applied methodologies, where deﬁnitions of
compliance and persistence were calculated differently. Race,
multiple dosing, mode of administration, and patients’ behav-
ioral factors were signiﬁcantly associated with adherence levels.
Economic consequences of poor adherence were identiﬁed from
seven studies (ﬁve retrospective, one patient survey, and one lon-
gitudinal cohort study), which demonstrated an increase in hos-
pitalizations, premature disability, and other adverse events
resulting in higher healthcare costs. Increasing co-payments (7
retrospective studies) resulted in a decrease in taking medications
leading to increased adverse events and subsequent healthcare
costs. CONCLUSIONS: This review conﬁrms the lack of ade-
quate treatment adherence among patients with diabetes and
illustrates the considerable economic impact. More sophisticated
methods of determining medication adherence have the poten-
tial to more accurately estimate adherence rates. Research
demonstrating adherence to insulin therapies, particularly insulin
pens, and related economic consequences are lacking in the 
literature.
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OBJECTIVE: The objective of this study was to investigate the
association between pain response and health-related quality of
life (HRQoL) in patients with diabetic peripheral neuropathic
pain (DPNP). METHODS: EQ-5D data was collected at base-
line and endpoint in three large placebo controlled randomised
trials which evaluated duloxetine treatment for DPNP over a 12-
week horizon. Patients had a clinical diagnosis of pain due to
bilateral peripheral neuropathy caused by diabetes, had a mean
24-hour average pain severity score ≥ 4 on the 11 point Likert
scale (“0 = no pain” and “10 = pain as bad as you can imagine”)
and suffered from daily pain for at least 6 months. Treatment
response was based on the level of change observed in the
average pain severity score. Three levels of clinically meaningful
pain response were deﬁned: full response (≥50% change in
average pain severity), partial response (30 to 49% change
average pain severity), and no response (<30% change in average
pain severity). Utility data at the trial endpoint were pooled and
stratiﬁed into the corresponding pain response thresholds.
RESULTS: Patients had pain and utility scores measured at base-
line (n = 1139) and trial endpoints (n = 998) across the three
randomised trials. The average pain score at baseline was 5.8 ±
1.5 with a corresponding utility score of 0.58 ± 0.26. At trial
endpoint, patients in the no response to treatment category had
lower utility scores (0.61 ± 0.24) compared to patients with
either a partial response (0.70 ± 0.16) or full response (0.78 ±
0.16). In addition, a statistically signiﬁcant negative correlation
was found, indicating that increasing pain severity was strongly
associated with lower HRQoL in DPNP patients. CONCLU-
SION: Pain response had a considerable impact on HRQoL in
DPNP patients. In addition, pain severity scores were signiﬁ-
cantly associated with lower HRQoL.
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OBJECTIVE: This study aimed to estimate the health-related
quality of life (HRQL) utility score for patients with diabetes
mellitus Type 1 and Type 2 on insulin and/or oral treatment using
EQ-5D and to compare differences in HRQL for controlled and
uncontrolled patients. METHODS: We surveyed 157 patients in
a cross sectional study with treated Type 1 and Type 2 diabetes
in Sweden (age range 20–65 years). Physicians recorded demo-
graphic and treatment information, including medications for
diabetes. HRQL was measured using the EQ-5D questionnaire
and was ﬁlled in by the patients at a physician visit. We evalu-
ated the differences between groups (e.g. treatment regimes)
using GLM-models. All statistical tests were performed at the
0.05-level of signiﬁcance and were all two-sided. EQ-5D was
linked to utility weights using an algorithm that converges
ordinal ratings into a weighed composite score. RESULTS: The
mean utility score for the entire sample was 0.81 (SD 0.21) with
a median of 0.79 (min -0.18, max 1.00). Patients with Type 1
diabetes had a higher mean utility score (0.88) than patients with
Type 2 diabetes. Patients treated with a mixed regimen of oral
antidiabetics and insulin reported a lower utility score (0.76).
However, differences between treatment groups were not signif-
icant at the 5% level (p = 0.063). No signiﬁcant difference was
estimated in the health utility score for patients with controlled
diabetes according to Swedish guidelines in comparison to
uncontrolled patients. Women had signiﬁcantly lower EQ-5D
utility score than men, 0.76 and 0.85 respectively (p = 0.0217).
The utility score ranged from 0.92 in the youngest age group
(age 20–45) to 0.78 to the oldest age group (age 61–65) (p =
0.02). CONCLUSION: Type 1 diabetes patients reported a
higher HRQL than Type 2 diabetes patients. Women had signif-
icantly lower EQ-5D score than men.
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OBJECTIVE: To test the hypothesis that improved nerve func-
tion using the anti-epileptic/migraine drug topiramate would
translate to better quality of life (QOL). METHODS: Twenty
patients with diabetic peripheral neuropathy were consented and
entered into a study on topiramate. The dosage for each patient
was titrated over a six-week period from 25mg per day to 50
mg twice a day. The patients remained on 100mg a day for 12
weeks and then were tapered off the medication over an addi-
tional 4-week period. Each patient received quantitative sensory
testing, electromyography, skin blood ﬂow, skin biopsies, and
neurological examinations before and after treatment with top-
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iramate. Each patient also answered the Norfolk Quality of Life
questionnaire for diabetic neuropathy (QOL-DN) before and
after treatment. The QOL-DN questionnaire was used to assess
the patients’ perception of the effects of diabetic peripheral neu-
ropathy on their quality of life. RESULTS: Total QOL: before =
27.76 ± 5.40, after = 17.29 ± 4.66 (P = 0.00028). Small ﬁber:
before = 2.35 ± 0.77, after = 1.59 ± 0.68 (p = 0.149). ADLs:
before = 1.83 ± 0.74, after = 1.22 ± 0.69 (p = 0.276). Symptom
Score: before = 8.28 ± 1.24, after = 3.39 ± 0.69 (p = 0.00004).
Autonomic Function: before = 1.06 ± 0.47, after = 1.00 ± 0.47
(p = 0.834). Large Fiber: before = 15.06 ± 3.30, after = 10.01 ±
2.79 (p = 0.0044). Topiramate signiﬁcantly improved 3 of the 5
domains of QOL-DN. There was a signiﬁcant correlation
between the changes in QOL symptom score and proximal leg
cold sensation (r = 0.459, p = 0.0448). In addition, the correla-
tion between changes in QOL large ﬁber neuropathy score and
objective changes in Total Neuropathy Score approached signif-
icance (r = 0.459, p = 0.0637). Thus, topiramate improves objec-
tive indices of nerve function and QOL. CONCLUSIONS: Nerve
Function improvement and enhanced QOL can be used as a
measure of response to therapy in clinical trials.
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OBJECTIVES: While measures of quality of life (QoL) have been
widely used in patients with Type 2 diabetes mellitus (T2DM),
there is insufﬁcient data on preference-weighted health status
measures like the Euroqol EQ-5D. This study reports statistical
relationships among the EQ-5D and QoL measures, and with co-
morbid conditions like obesity and depression. METHODS:
Patients with T2DM at the outpatient clinics of a university hos-
pital completed a mailed questionnaire which included the EQ-
5D in addition to measures of generic health status (SF-12),
diabetes-speciﬁc QoL (Audit of Diabetes Dependent Quality of
Life-ADDQoL), and depressive symptoms (Center for Epidemi-
ologic Studies Depression—CES-D). Patient reported data were
merged with retrospective clinical data from electronic medical
records. RESULTS: Usable response rate was 44.3% (n = 385).
Average EQ-5D score was 0.71 (±0.21). Spearman correlations
with the EQ-5D index were: SF PCS-12 (0.640), SF MCS-12
(0.534), CES-D (-0.578), ADDQoL (0.316). Average EQ-5D
scores were signiﬁcantly lower for patients on oral medications
and insulin (0.65 ± 0.22) compared to those only on oral med-
ications (0.76 ± 0.19) (p < 0.001), and in those with at least one
diabetes-related complication (0.68 ± 0.22) compared to those
without (0.74 ± 0.21) (p = 0.011). There were no signiﬁcant dif-
ferences on the basis of glycemic control levels obtained from
patients’ A1C. Approximately 86% of those reporting no
anxiety and depression on the EQ-5D were classiﬁed as not
having depressive symptoms on the CES-D (Chi Square = 144.6,
p < 0.001; Somer’s d = 0.66, p < 0.001). Nearly 73% of patients
reporting moderate problems with mobility and usual activities
each on the EQ-5D were clinically obese. Simple linear regres-
sion indicated that the SF PCS-12 and SF MCS-12 together
explained 57% of the variance in EQ-5D scores. CONCLU-
SIONS: EQ-5D scores reﬂected deﬁcits in health status on the
basis of diabetes severity variables like treatment type and dia-
betes-related complications, as well as conditions co-morbid to
T2DM like obesity and depression.
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It has been shown in the literature that quality of life differs by
anti-diabetic treatment. OBJECTIVE: This study investigates
salient differences between exenatide and insulin—products that
show similar efﬁcacy for the treatment of type 2 diabetes.
Namely, compared with insulin, exenatide is associated with
weight loss rather than weight gain and a higher incidence of
nausea early in treatment. The current study used standard
gamble (SG) methodology to estimate the utility/disutility of
these attributes. METHODS: Hypothetical diabetes-related
health states (with variations in nausea and weight) were created
based on clinical trial data and the input of clinical experts and
patients. Patients in Scotland and England with type 2 diabetes
rated these health states and their own current health state in 
SG interviews. Patients completed the EQ-5D, PGWB, and 
the Appraisal of Diabetes Symptoms (ADS). Construct validity
and health state differences were examined with correlations, 
t-tests, and ANOVAs. RESULTS: A total of 129 patients (51
Scotland;78 England) completed standard gamble interviews.
The mean utility of a health state at the patients’ current weight
without nausea was 0.89. Higher weight was associated with
lower utility, and lower weight was associated with higher utility
(e.g., 5% higher weight = 0.83; 3% higher weight = 0.85; 3%
lower weight = 0.91; 5% lower weight = 0.92). Differences
between health states that varied by weight were statistically sig-
niﬁcant (e.g., current weight vs. 3% higher and 3% lower; both
p < 0.001). Health states with nausea were rated signiﬁcantly
lower than otherwise identical health states without nausea (p <
0.001). SG ratings of own health (mean = 0.87) demonstrated
construct validity through signiﬁcant correlations with patient-
reported outcome measures. CONCLUSIONS: Findings suggest
that patient standard gamble interviews are a feasible method
for obtaining utilities for type 2 diabetes utilities/disutilities. The
utilities obtained in this study would be appropriate for use in a
cost-utility analysis of treatment for type 2 diabetes.
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OBJECTIVES: To describe and compare the domains and psy-
chometric properties of selected instruments used in diabetes
Type 1 and Type 2. METHODS: A systematic literature review
of published studies was conducted using MEDLINE
(1990–2005), EMBASE (1990–2005) and the Mapi Research
Trust databases. Only studies describing the development or use
of a referenced instrument assessing QOL, treatment satisfaction
or adherence in patients with diabetes type 1 or 2 were reviewed.
Articles including diabetic patients after transplantation were not
included. RESULTS: Thirty instruments were identiﬁed: four for
patients under Insulin treatment (type 1 & 2), two for type 2
diabetes, nine “diabetes generic” (type 1 and type 2 treated with
Diet or tablets and/or insulin), ﬁve for devices, three for adher-
ence, two for diabetic complications, two were batteries and
three were generic questionnaires. Out of these only nine had
good psychometric properties. Three of them were fully vali-
dated, including responsiveness: the DQLCTQ for insulin-
